SAN FRANCISCO, Oct. 19 /PRNewswire/ -- Velos, Inc., an innovative clinical research software provider, today announced completion of electronic trial data submissions on Velos eResearch by a cooperative of leading cancer research centers. Velos eResearch supports collaborative research and automates the clinical trials process from source systems, such as labs, adverse events and medical record systems, through data submission to clinical trial sponsors using Velos’ grid architecture. This is a significant milestone in clinical research automation as it is the first multi-center, electronic submission of clinical trial data from source information systems through to the National Cancer Institute.
Supported in part by grants from the Prostate Cancer Foundation and Memorial-Sloan Kettering, the Velos-based research cooperative includes:
-- Memorial Sloan-Kettering Cancer Center -- UCSF Comprehensive Cancer Center -- Dana-Farber Cancer Institute -- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins -- University of Michigan Comprehensive Cancer Center -- University of Wisconsin Comprehensive Cancer Center
“Velos eResearch will accelerate the information sharing process among medical centers of excellence participating in clinical trials and speed up the process of drug development,” said Dr. Howard I. Scher, Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering. “We expect this to have a major impact on clinical trials in that it will allow Centers to reduce costs, improve the quality of study data, eliminate the chance of error, and help trial sites communicate more efficiently and effectively.”
Unlike most Electronic Data Capture approaches, with Velos, investigators and research sponsors create multi-organization networks of researchers running multiple clinical trials without changing the underlying system for each study. This single system approach fundamentally alters the economics and automation potential for clinical trials.
“As part of our mission to accelerate the development of better treatments and a cure for prostate cancer, we must improve the efficiency of the clinical trials process. By adopting a common data system, these leading academic centers, all of which are members of our Therapy Consortium, have taken an important step in the right direction. This will make it easier for more patients to participate in clinical trials and help everyone benefit from the results of those trials sooner,” said Leslie D. Michelson, Vice Chairman and CEO of the Prostate Cancer Foundation.
Velos, Inc. (http://www.velos.com/) is a leading designer and developer of next-generation healthcare information systems. Velos eResearch (http://www.veloseresearch.com/) has been purchased by five of the top ten hospitals, four of the top ten cancer centers, and three of the top ten cardiology and cardiology surgery centers in the United States. Velos is privately held with headquarters in Silicon Valley.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.
Velos, Inc.
CONTACT: Madalynne Chapman of Velos, Inc., +1-510-580-2661, ormchapman@velos.com
Web site: http://www.veloseresearch.com/
Web site: http://www.velos.com/